Although no differences were observed for other pro- (IL-1β, MIF, TNF-α, IL-8, IL-17A) and anti-inflammatory (IL-10) markers, studies suggest that n-3 supplementation reduces CRP levels in colorectal cancer and CRP and IL-6 in lung cancer. This evidence concerns the gene IL6 and lung carcinoma.